<DOC>
	<DOCNO>NCT00882973</DOCNO>
	<brief_summary>This phase I/II trial determine maximum tolerate dose recommended phase II dose combination therapy Genexol-PM gemcitabine ( hereafter Genexol-PM plus gemcitabine ) evaluate efficacy safety Genexol-PM regimen ( monotherapy combination gemcitabine ) gemcitabine monotherapy subject locally advanced metastatic pancreatic cancer .</brief_summary>
	<brief_title>Trial Determine Maximum Tolerated Dose Genexol-PM Plus Gemcitabine Evaluate Efficacy Safety Genexol-PM Regimens Subjects With Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Subjects age 18 year old 2 . Subjects whose write informed consent obtain comply local regulatory requirement prior participation trial 3 . Subjects histologically cytologically confirm unresectable metastatic epithelial cancer exocrine pancreas . Highquality contrastenhanced CT scan require evaluate resectability . Measurable disease require . 4 . Subjects malignancy diagnose within past five year except : Cured nonmelanoma skin cancer Cured cervical intraepithelial neoplasia ( CIN ) Cured Insitu cervical cancer ( CIS ) 5 . Subjects ECOG performance status â‰¤ 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>